Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.53 |
| ▸ | ATM | Q13315 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 4/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | UBE2M | P61081 | 1/20 | 0.45 |
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.45 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.45 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.45 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | RAD52 | P43351 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | TP53 | P04637 | 2/20 | 0.43 |
| ▸ | SHMT2 | P34897 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7762749 | 1.00 | EPHX1 (0.53) | EPHX1ATMRAB9AKMT2AUBE2M | |
| SCHEMBL7762757 | 1.00 | EPHX1 (0.53) | EPHX1ATMRAB9AKMT2AUBE2M | |
| SCHEMBL7765483 | 1.00 | EPHX1 (0.53) | EPHX1ATMRAB9AKMT2AUBE2M | |
| SCHEMBL285807 | 1.00 | EPHX1 (0.53) | EPHX1ATMRAB9AKMT2AUBE2M | |
| SCHEMBL7765477 | 1.00 | EPHX1 (0.53) | EPHX1ATMRAB9AKMT2AUBE2M | |
| SCHEMBL7767368 | 1.00 | EPHX1 (0.53) | EPHX1ATMRAB9AKMT2AUBE2M | |
| SCHEMBL7767298 | 1.00 | EPHX1 (0.53) | EPHX1ATMRAB9AKMT2AUBE2M | |
| SCHEMBL7765468 | 1.00 | EPHX1 (0.53) | EPHX1ATMRAB9AKMT2AUBE2M | |
| SCHEMBL7762723 | 0.99 | EPHX1 (0.51) | EPHX1ATMRAB9AKMT2AUBE2M | |
| SCHEMBL7762720 | 0.99 | EPHX1 (0.51) | EPHX1ATMRAB9AKMT2AUBE2M |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050192245-A1 | Medicinal composition for treating arteriosclerosis | SANKYO COMPANY, LIMITED (JP) | 2005-09-01 | — | — | US | claimed |
| EP-1555032-A1 | MEDICINAL COMPOSITION FOR TREATING ARTERIOSCLEROSIS | Sankyo Company, Limited (JP) | 2005-07-20 | — | — | EP | claimed |
| EP-0718281-B1 | CYCLOHEXANEDIUREA DERIVATIVE AND PROCESS FOR PRODUCING THE SAME | NISSIN FOOD PRODUCTS LTD (JP) | 2001-06-27 | — | — | EP | claimed |
| EP-0718281-A1 | CYCLOHEXANEDIUREA DERIVATIVE AND PROCESS FOR PRODUCING THE SAME | NISSIN FOOD PRODUCTS CO., LTD. (JP) | 1996-06-26 | — | — | EP | claimed |
| US-10925885-B2 | Thyromimetics for the treatment of fatty liver diseases | METABASIS THERAPEUTICS, INC. (US) | 2021-02-23 | — | — | US | disclosed |
| US-10420781-B2 | Thyroid hormone receptor agonist and use thereof | METABASIS THERAPEUTICS INC. (US) | 2019-09-24 | — | — | US | disclosed |
| US-20190083515-A1 | THYROMIMETICS FOR THE TREATMENT OF FATTY LIVER DISEASES | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2019-03-21 | — | — | US | disclosed |
| US-20180344752-A1 | THYROID HORMONE RECEPTOR AGONIST AND USE THEREOF | METABASIS THERAPEUTICS INC. | 2018-12-06 | — | — | US | disclosed |
| US-10130643-B2 | Thyromimetics for the treatment of fatty liver diseases | METABASIS THERAPEUTICS, INC. (US) | 2018-11-20 | — | — | US | disclosed |
| US-20170319604-A1 | THYROID HORMONE RECEPTOR AGONIST AND USE THEREOF | METABASIS THERAPEUTICS, INC. | 2017-11-09 | — | — | US | disclosed |
| WO-2017184811-A1 | THYROID HORMONE RECEPTOR AGONIST AND USE THEREOF | METABASIS THERAPEUTICS, INC. (US) | 2017-10-26 | — | — | WO | disclosed |
| US-20170112864-A1 | Thyromimetics for the Treatment of Fatty Liver Diseases | METABASIS THERAPEUTICS, INC. (US) | 2017-04-27 | — | — | US | disclosed |
| WO-2005051298-A2 | NOVEL PHOSPHORUS-CONTAINING THYROMIMETICS | METABASIS THERAPEUTICS, INC. (US) | 2005-06-09 | — | — | WO | disclosed |
| US-20050118226-A1 | Sustained-release implant releases ACAT inhibitor for a time effective to reduce ACAT activity; Alzheimer's disease, atherosclerosis; amyloid- beta reduction | GENERAL HOSPITAL CORPORATION, THE | 2005-06-02 | — | — | US | disclosed |
| US-20050119314-A1 | Pharmaceutical composition comprising an ACAT inhibitor and an insulin resistance reducing agent | SANKYO COMPANY, LIMITED (JP) | 2005-06-02 | — | — | US | disclosed |
| EP-1493448-A1 | MEDICINAL COMPOSITION COMPRISING ACAT INHIBITOR AND INSULINE RESISTANCE IMPROVING AGENT | Sankyo Company, Limited (JP) | 2005-01-05 | — | — | EP | disclosed |
| US-20040198788-A1 | Medicinal compositions containing angiotensin II receptor antagonist | SANKYO COMPANY, LIMITED (JP) | 2004-10-07 | — | — | US | disclosed |
| EP-1421953-A1 | MEDICINAL COMPOSITIONS CONTAINING ANGIOTENSIN II RECEPTOR ANTAGONIST | Sankyo Company, Limited (JP) | 2004-05-26 | — | — | EP | disclosed |
| EP-0718281-B1 | CYCLOHEXANEDIUREA DERIVATIVE AND PROCESS FOR PRODUCING THE SAME | NISSIN FOOD PRODUCTS LTD (JP) | 2001-06-27 | — | — | EP | disclosed |
| EP-0718281-A1 | CYCLOHEXANEDIUREA DERIVATIVE AND PROCESS FOR PRODUCING THE SAME | NISSIN FOOD PRODUCTS CO., LTD. (JP) | 1996-06-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170112864-A1 | Thyromimetics for the Treatment of Fatty Liver Diseases | TSHR, THRA, FABP1 | EPHX1 1344/4885ATM 3299/4885RAB9A 3593/4885 |
| US-10420781-B2 | Thyroid hormone receptor agonist and use thereof | THRB, THRA, TSHR | EPHX1 2700/4885ATM 2844/4885RAB9A 1188/4885 |
| US-10925885-B2 | Thyromimetics for the treatment of fatty liver diseases | TSHR, THRA, FABP1 | EPHX1 1344/4885ATM 3299/4885RAB9A 3593/4885 |
| US-20040198788-A1 | Medicinal compositions containing angiotensin II receptor antagonist | AGTR2, AGTR1, AGT | EPHX1 1461/4885ATM 2788/4885RAB9A 3792/4885 |
| US-20190083515-A1 | THYROMIMETICS FOR THE TREATMENT OF FATTY LIVER DISEASES | TSHR, THRA, FABP1 | EPHX1 1343/4885ATM 3295/4885RAB9A 3581/4885 |
| US-20180344752-A1 | THYROID HORMONE RECEPTOR AGONIST AND USE THEREOF | THRB, THRA, TSHR | EPHX1 2700/4885ATM 2844/4885RAB9A 1188/4885 |
| US-20170319604-A1 | THYROID HORMONE RECEPTOR AGONIST AND USE THEREOF | THRB, THRA, TSHR | EPHX1 2700/4885ATM 2844/4885RAB9A 1188/4885 |
| US-10130643-B2 | Thyromimetics for the treatment of fatty liver diseases | TSHR, THRA, FABP1 | EPHX1 1344/4885ATM 3299/4885RAB9A 3593/4885 |
| US-20050119314-A1 | Pharmaceutical composition comprising an ACAT inhibitor and an insulin resistance reducing agent | ACAT2, ACAT1, ACACA | EPHX1 1688/4885ATM 793/4885RAB9A 3692/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.